Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
Purpose
This is a randomized, open-label, multi-site Phase II study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report, who were eligible to undergo definitive resection, have demonstrated laboratory, radiographic and/or pathologic high-risk criteria for recurrence (described under eligibility), have no evidence of disease (NED) as per MRI approximately 28 days post resection, and are able to provide a tissue sample for personalized neoantigen DNA vaccine development.
Condition
- HCC
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Written informed consent 2. ≥18 years of age 3. Histologically or cytologically confirmed diagnosis of HCC (not accepted: fibrolamellar, sarcomatoid, mixed cholangiocarcinoma) 4. Child-Pugh Class A liver score 5. Documented virology status of hepatitis 6. Availability of a representative post-resection tumor tissue sample 7. ECOG performance status of 0 or 1 8. Adequate organ function 9. Women of childbearing potential (WOCBP) and men must be willing to use an adequate method of contraception
Exclusion Criteria
- Is currently participating in and receiving study drug or has participated in a study of an investigational agent and received study drug or used an investigation device, within 4 weeks to baseline 2. Evidence of residual, recurrent, or metastatic disease at randomization 3. Active or history of autoimmune disease or immune deficiency 4. Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug 5. Diagnosed additional malignancy within 5 years prior to baseline, except for: (a) non-invasive carcinomas subject to successful curative treatment in the opinion of the investigator which require no further therapy and (b) other malignancies for which subjects have undergone potentially curative therapy and have been considered disease free for at least 3 years prior to screening. 6. Active infection requiring systemic therapy 7. Is pregnant, breastfeeding or expecting to conceive or father children within the study's projected duration 8. History of human immunodeficiency virus (HIV) (HIV I/II antibodies). 9. Co-infection with HBV and hepatitis D viral infection 10. Co-infection with HBV and HCV 11. Has received a live vaccine within 30 days of planned start of study
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Intervention Model Description
- Adjuvant Therapy, Active Surveillance
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Personalized Immunotherapy for Cancer: |
GNOS-PV02 + INO-9012 ID followed by electroporation every 3 weeks for 4 doses, then every 9 weeks (Q9W) until week 104, then every 12 weeks (Q12W) until week 260 followed by 3 years follow-up survival |
|
|
No Intervention Standard of Care |
Active Surveillance for 5 years or until recurrence, plus 3 years follow-up survival. |
|
Recruiting Locations
Johns Hopkins University
Baltimore, Maryland 21287
Baltimore, Maryland 21287
More Details
- Status
- Recruiting
- Sponsor
- Geneos Therapeutics